Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study.
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
Multifocal Tumefactive Demyelination Mimicking Intracranial Neoplasm.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Getting a Handle on Lymphopenia With Tecfidera
Pushing Forward: Remyelination as the New Frontier in CNS Diseases.
Product Portfolio, Meda
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Improvements in cognition, quality of life, and physical performance with clinical Pilates in multiple sclerosis: a randomized controlled trial.

Pages